Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
Spero Therapeutics (Nasdaq: SPRO) announced a conference call on May 6, 2021, at 4:30 p.m. ET to discuss its Q1 2021 financial results and provide a business update.
The company focuses on developing novel treatments for multi-drug-resistant infections and rare diseases, with its lead candidate, tebipenem HBr, showing positive Phase 3 trial results for complicated urinary tract infections. Spero is also developing SPR720 for orphan pulmonary diseases and SPR206 targeting MDR Gram-negative infections.
- Positive results from Phase 3 ADAPT-PO trial for tebipenem HBr.
- Focus on high unmet medical needs in multi-drug-resistant infections.
- None.
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m. ET to report its first quarter 2021 financial results and provide an update on its business and pipeline.
To access the call please dial 877-705-6003 (domestic) or 201-493-6725 (international) and refer to conference ID 13718122. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.
About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.
Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-430-7577
Media Contact:
media@sperotherapeutics.com
FAQ
What is Spero Therapeutics' stock symbol?
When will Spero Therapeutics report its Q1 2021 financial results?
What is Spero Therapeutics developing?
What are the results of Spero's Phase 3 trial?
What candidates are in Spero's pipeline?
